Platelet Release Reaction in vivo in Patients with Ischaemic Heart Disease after Isometric Exercise and its Prevention with Dipyridamole

Summary

In 20 patients with ischaemic heart disease (IHD), platelet sensitivity to ADP- aggregation, plasma von Willebrand factor (vWF) and plasma β-thromboglobulin (β-TG) were measured before and after isometric exercise. Effect of dipyridamole on these determinants was studied in a crossover fashion. To assess plasma vWF level, a new simple method was employed which has the advantage of not requiring an optical aggregometer and was proved to be reproducible.

No significant difference was seen in platelet sensitivity to ADP-aggregation, vWF and β-TG among healthy controls, IHD patients on placebo and on dipyridamole at rest. After exercise, platelet sensitivity to aggregation, plasma vWF and β-TG increased significantly in IHD patients on placebo. In healthy controls, no significant changes were seen. On dipyridamole, above changes seen in IHD patients were not seen.

The results suggests that isometric exercise may induce platelet release reaction in vivo and may produce hypercoagulable state in IHD patients. These phenomena may be prevented by pretreatment with dipyridamole.

• References

• 1 Bensoussan D, Levy-Toledano S, Passa P, Caen J, Canivet J. 1975; Platelet hyperaggregation and increased plasma level of von Willebrand factor in diabetics with retinopathy. Diabetologia 11: 307
• 2 Best LC, Martin TJ, Mcguire MB, Preston FE, Russell RG G, Segal DS. 1978; Dipyridamole and platelet function. Lancet 2: 846
• 3 Denham MJ, Fisher M, James G, Hassan M. 1977; α-thromboglobulin and heparinneutralising activity test in clinical conditions. Lancet 1: 1154
• 4 Fuster V, Bowie EJ W, Lewis JC, Fass DN, Owen Jr CA, Brown AL. 1978; Resistance to arteriosclerosis in pigs with won Willebrand's disease. Spontaneous and high cholesterol diet-induced arteriosclerosis. Journal of Clinical Investigation 61: 722
• 5 Ludlam CA, Bolton AE, Moore S, Cash JD. 1975; New rapid method for diagnosis of deep venous thrombosis. Lancet 2: 259
• 6 Macfarlane DE, Stebbe J, Kirby EP, Zucker MB, Grant RA, Mcpherson J. 1975; A method for assaying von Willebrand factor (ristocetin cofactor). Thrombosis et Diathesis haemorrhagica 34: 306
• 7 Moncada S, Korbut R. 1978; Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1: 1286
• 8 Moore S, Pepper DS, Cash JD. 1975; The isolation and characterisation pf a platelet-specific beta-globulin (β-thromboglobulin) and the detection of anti-urokinase and antiplasmin released from thrombin-aggregated washed human platelets. Biochemica et Biophysica Acta 379: 360
• 9 Nachman RL, Jaffe EA. 1976; The platelet-endothelial cell-VIII axis. Thrombosis and Haemostasis 35: 120
• 10 Sano T, Motomiya T, Yamazaki H, Shimamoto T. 1977; Enhancement of platelet sensitivity to ADP-aggregation by isometric exercise in arteriosclerotic patients and its prevention. Thrombosis and Haemostasis 37: 329
• 11 Sarji KE, Nair RM G, Chambers AL, Laimins M, Smith TM, Colwell JA. 1975; Increased levels of von Willebrand Factor (vWF) and platelet aggregation in diabetes mellitus. Diabetes 24 Supplement (Suppl. 02) 398
• 12 Tschopp TB, Weiss HJ, Baumgartner HR. 1974; Decreased adhesion of platelets to subendothelium in von Willebrand's disease. Journal of Laboratory and Clinical Medicine 83: 296
• 13 World Health Organization Expert Committee On Arterial Hypertension And Ischemic Heart Disease. 1962; Arterial hypertension and ischemic heart disease: preventive aspects. World Health Organization Technical Report Series 231: 1